Departments of 1 Pharmacology and 2 Anesthesiology, College of Medicine, University of Illinois, Chicago, Illinois 60612
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We determined the concentration
dependence of albumin binding, uptake, and transport in confluent
monolayers of cultured rat lung microvascular endothelial cells
(RLMVEC). Transport of 125I-albumin in RLMVEC
monolayers occurred at a rate of 7.2 fmol · min1 · 106
cells
1. Albumin transport was inhibited by cell surface
depletion of the 60-kDa albumin-binding glycoprotein gp60 and by
disruption of caveolae using methyl-
-cyclodextrin. By contrast, gp60
activation (by means of gp60 cross-linking using primary and secondary
antibodies) increased 125I-albumin uptake 2.3-fold. At
37°C, 125I-albumin uptake had a half time of 10 min and
was competitively inhibited by unlabeled albumin (IC50 = 1 µM). Using a two-site model, we estimated by Scatchard analysis
the affinity (KD) and maximal capacity
(Bmax) of albumin uptake to be 0.87 µM
(KD1) and 0.47 pmol/106 cells
(Bmax1) and 93.3 µM (KD2) and 20.2 pmol/106 cells (Bmax2). At 4°C, we also
observed two populations of specific binding sites, with high
(KD1 = 13.5 nM, 1% of the total) and low
(KD2 = 1.6 µM) affinity. On the basis of
these data, we propose a model in which the two binding affinities
represent the clustered and unclustered gp60 forms. The model predicts
that fluid phase albumin in caveolae accounts for the bulk of albumin
internalized and transported in the endothelial monolayer.
capillary permeability; vesicular transport; caveolae; albumin-binding glycoprotein gp60
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THERE IS ACCUMULATING EVIDENCE from morphological and functional studies that albumin is continuously exchanged between the microvascular and interstitial compartments by receptor-mediated albumin transcytosis (8, 11, 13, 16-19, 23, 27-29). Recent studies show that albumin molecules can associate with surface glycoproteins such as gp60 (albondin) in endothelial cells, which can activate the transport of albumin (2, 6-8, 13, 19, 20, 23, 25, 28, 29). The signaling pathways mediating transcytosis are not well understood. The pathway involving the heterotrimeric G protein Gi and the activation of Src kinase signaling may activate albumin endocytosis and its transport from the luminal to the abluminal cell surface (12-14, 27). Interestingly, albumin transcytosis was augmented by antibody-induced cross-linking of gp60 (13, 27-29). These studies suggest that, under physiological conditions, albumin can bind to its cell surface receptors [the albumin-binding proteins (ABPs)] and initiate transcytosis.
However, important issues concerning the mode of albumin uptake and transport by a transcellular route remain unresolved. Fluid phase transport of albumin in vesicles or via the paracellular pathway would not be expected to be a saturable process, whereas transport of albumin, either bound to receptors or regulated by receptors, should be saturable. In addition, the high-affinity nature of ABPs such as gp60 (in the nanomolar range) (19, 25) relative to plasma and interstitial concentrations of albumin (<1 mM) implies that 1) albumin uptake and transcytosis should be constitutive processes and 2) bound albumin may not dissociate from its vesicular carriers upon exocytosis. These questions could not be previously addressed with any rigor, because determinations of affinity of albumin to the endothelial plasmalemma were hampered by high nonspecific binding (2, 6, 7, 19). This masked any saturable and specific albumin binding. In the present study, we determined the concentration dependency of albumin binding on the surface of confluent endothelial monolayers and transport of albumin. We specifically used cultured rat lung microvascular endothelial cells (RLMVEC), because they were shown by us to have low nonspecific cell surface adsorption of albumin. We show that 1) binding and uptake of albumin have saturable and fluid phase components, 2) cellular uptake of albumin is submaximal at physiological serum albumin concentration, implying that it can be further increased in response to appropriate signals, and 3) gp60, an ABP, can activate albumin transport.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Endothelial Cell Cultures
RLMVEC (VEC Technologies, Rensselaer, NY) were cultured in high-glucose DMEM (GIBCO BRL, Grand Island, NY) supplemented with 5% fetal bovine serum (Hyclone, Logan, UT) plus 50 U/ml penicillin and 50 µg/ml streptomycin, as described previously (4). The cultures were maintained in 5% CO2-95% room air at 37°C.Drugs and Reagents
All drugs and reagents were obtained from Sigma Chemical (St. Louis, MO) unless stated otherwise. Hanks' balanced salt solution (HBSS) containing NaHCO3 (4.2 mM) and HEPES (10 mM) was adjusted to pH 7.4. Bovine serum albumin (fraction V, 99% pure, endotoxin free, cold alcohol precipitated) was freshly dissolved in HBSS in concentrations of 0.01-100 mg/ml. Methyl-Albumin Iodination
Labeling of albumin with Na-125I (ICN Pharmaceuticals) was performed using chloramine T (3). The tracer albumin formed was purified to <0.4% free 125I using Sephadex G-25 columns (Sigma Chemical). Specific radioactivity was 0.3-1.0 µCi/µg albumin determined by 10% trichloroacetic acid precipitation.Methyl--Cyclodextrin Treatment
Immunostaining
Cellular localization of albumin, gp60, and caveolin-1 in the plasma membrane and plasmalemmal vesicles exposed to albumin was determined by immunocytochemical labeling and laser scanning confocal microscopy (LSM 510, Zeiss). RLMVEC were serum deprived for 2 h, washed three times with HEPES-buffered HBSS or phenol red-free DMEM, and exposed to 0.1 mg/ml albumin in the presence of 50 µg/ml Alexa 488-conjugated albumin, 20 µg/ml cholera toxin subunit B-Alexa 594 conjugate, and/or 3.5 µg/ml Cy3-anti-gp60 antibody for up to 30 min (13). Cells were then washed three times with HBSS, fixed with 4% paraformaldehyde in HBSS, and blocked for 30 min in HBSS containing 5% goat serum, 0.1% Triton X-100, and 0.01% NaN3. Primary antibody labeling was performed overnight at 4°C with anti-caveolin-1 antibody (1 µg/ml). Coverslips were then washed three times for 10 min in HBSS, blocked for 30 min with 5% goat serum, and incubated for 2 h at room temperature with fluorescent-labeled goat anti-rabbit and goat anti-mouse secondary antibody. In some cases, 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, 1 µg/ml) was added to visualize the nucleus. Confocal microscopy was performed using 364-, 488-, and 568-nm excitation laser lines to detect DAPI/Alexa 350 (band pass 385-470 nm emission), FITC/Alexa 488 (band pass 505-550 nm emission), and rhodamine/Alexa 568 fluorescence (long pass 585 nm emission) in optical sections <1 µm thick (pinhole set to achieve 1 Airy unit).Cell Surface gp60 Cross-Linking
RLMVEC monolayers were washed twice with HEPES-buffered DMEM at 4°C and incubated for 30 min at 4°C with anti-gp60 antibody (20 µg/ml) and then with secondary antibody (goat anti-rabbit, 20 µg/ml) for 30 min to cross-link gp60. Controls were treated with the preimmune antibody (20 µg/ml) at 4°C for 30 min. Cells were rewarmed to 37°C to activate endocytosis (27). To deplete ABP gp60 (27), anti-gp60 antibody was preincubated with cells for 2 h at 37°C.Binding of 125I-Albumin
Confluent cell cultures in six-well plates (1.0-1.2 × 106 cells/35 mm) were washed twice in 10 mM HEPES-buffered DMEM, pH 7.4, and then serum deprived for 2 h by incubation in DMEM. Cells were precooled to 4°C for 30 min, and 125I-albumin in the presence or absence of unlabeled albumin in HBSS was added for 30 min at 4°C. Unbound ligand was removed by three washes with ice-cold HBSS, and cells were lysed with 1 ml of 50 mM Tris · HCl buffer, pH 7.4, containing 1% Triton X-100 and 0.5% SDS (13). Cell-associated 125I-albumin counts were measured in a gamma counter (Packard Instruments, Downers Grove, IL).Uptake of 125I-Albumin
Serum-deprived confluent RLMVEC monolayers (see above) were pretreated with indicated reagents at 37°C for required periods before addition of 125I-albumin in the presence or absence of unlabeled albumin in HBSS. Uptake at 37°C was allowed to proceed for times indicated and then terminated by chilling on ice and washing three times with ice-cold HBSS. To remove cell surface-bound 125I-albumin, cells were washed three times with 1 ml of acid wash buffer (0.5 M NaCl and 0.2 M acetic acid, pH 2.5) (26). Cells were then lysed and counted as described above.Transendothelial 125I-Albumin Transport
RLMVECs were grown on clear microporous polyester Transwell membranes (12 mm diameter, 1 cm2 growth area, 0.4 µm pore size; Corning Costar, Cambridge, MA). The membrane inserts were filled with a total of 0.5 ml of incubate containing 125I-albumin in the presence or absence of unlabeled albumin. The lower well was filled with 1.5 ml of incubate of the same osmolarity as the inner well. Thus fluid levels and osmotic pressure in the "upper" and "lower" wells were equalized to minimize hydrostatic and osmotic effects. Labeled albumin and test agents were added to the upper well in equimolar solution, and transendothelial 125I-albumin permeability was measured at 37°C. Aliquots of 50 µl were sampled from the lower chamber every 10-15 min, and gamma radioactivity was measured. Albumin permeability was calculated for radiolabeled albumin flux across the cell monolayer, as described elsewhere (5, 22). Trichloroacetic acid precipitation analysis and SDS-PAGE of the tracer albumin (27) in the abluminal chamber showed that the radioactivity measured on the abluminal side of the cell monolayer remained attached to albumin and that albumin was not hydrolyzed in the uptake or transport process.Statistical Analysis
Data were analyzed by the nonlinear least-squares curve-fitting programs LIGAND (Elsevier Biosoft) and Microcal Origin (Microcal Software, Northhampton, MA). Student's t-test was used to compare results at significance level of P < 0.05. Multiple comparisons were made by ANOVA. All statistical tests were made using GraphPad Prism Instat software (San Diego, CA). ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Albumin Transport in Endothelial Monolayers
Time course of transendothelial 125I-albumin transport.
For studies of transendothelial 125I-albumin transport in
the apical-to-basolateral direction, RLMVEC were grown to
confluence on Transwell filter inserts (1-cm2 surface
area). Experiments began when the liquid in the upper well was replaced
by a warm (37°C) solution containing 125I-albumin plus
unlabeled albumin (1.5 µM or 0.1 mg/ml). During the 90-min period,
aliquots of media (0.05 ml) in the lower well were sampled and analyzed
for gamma radioactivity (see METHODS). Appearance of tracer
albumin in the basal chamber vs. time described a straight line (Fig.
1), as predicted if the backflux of
tracer (into upper chamber) was negligible. From the slope of the
fitted line in Fig. 1, we calculated the 125I-albumin flux
of 7.2 fmol · min1 · 106
cells
1. Excess unlabeled albumin (1.5 mM or 100 mg/ml)
blocked 125I-albumin flux (Fig. 1), implying competition
between labeled and unlabeled albumin at the apical endothelial
plasmalemmal surface.
|
Cell pathway regulates albumin transport.
The effect of methyl--cyclodextrin, the cholesterol-binding agent
that disrupts caveolae (10), on transendothelial
125I-albumin permeability was assessed. RLMVEC monolayers
grown on Transwell filter inserts received vehicle (without drug) or
methyl-
-cyclodextrin (0.2 nM-10 mM) for 15 min in the upper
chamber, and tracer albumin was added immediately thereafter.
Methyl-
-cyclodextrin blocked transendothelial
125I-albumin permeability with an IC50 of
~1.0 µM (Fig. 2). The highest concentration of the inhibitor (10 mM) reduced permeability of the
albumin tracer by ~80% (from 7.7 to 1.5 fmol · min
1 · 106
cells
1), indicating the importance of the cellular
pathway in albumin transport in RLMVEC.
|
Regulation of transendothelial albumin transport by gp60.
Inasmuch as activation of gp60 can stimulate albumin endocytosis in
endothelial cells via caveolae (13, 21, 27), we determined
whether gp60 activation also increased the transport of tracer albumin.
To prevent internalization of the antigen-antibody complex, gp60 on the
apical cell surface was cross-linked, as described elsewhere
(27), using an anti-gp60 antibody for 30 min in cold
conditions (4°C). Cells were rapidly rewarmed to 37°C with a
solution containing 125I-albumin (2.5 nM) plus unlabeled
albumin (1.5 µM) to activate uptake of the tracer. Control cultures
received isotype-matched antibody in lieu of anti-gp60 antibody.
Cross-linking of gp60 significantly increased 125I-albumin
permeability 2.3-fold above the control value of 38 ± 1.5 nl · min1 · cm
2.
Excess unlabeled albumin (1 mM) reduced 125I-albumin
permeability to 1.2 ± 0.6 nl
min
1 · cm
2 (Fig.
3) in the cells subjected to gp60
cross-linking. To address the dependence of basal transport of tracer
albumin on the cell surface gp60, RLMVEC monolayers were incubated with
anti-gp60 antibody for 2 h at 37°C to deplete cell surface gp60
(9, 27). This procedure reduced basal transendothelial
125I-albumin permeability to 7.3 ± 0.6 nl
min
1 · cm
2 (80%
inhibition; Fig. 3).
|
Albumin Uptake in Endothelial Cell Monolayers
Time course of tracer albumin uptake.
RLMVEC monolayers were incubated for various periods with
125I-albumin in the presence of 1.5 µM unlabeled albumin.
125I-albumin accumulation within the cells was determined
by counting gamma radioactivity in cell lysates. Lysates were prepared
from acid-washed cells to avoid contamination by tracer albumin
associated with the cell exterior. The time course of cellular
125I-albumin uptake was biphasic (Fig.
4). Specific tracer uptake (125I-albumin uptake in the presence of 1.5 µM albumin
minus that in 1.5 mM albumin) reached an initial peak (60 fmol/106 cells) within 15 min, approached a minimum (50 fmol/106 cells) at 30-45 min, and finally rose to a
second peak (75 fmol/106 cells) at 75 min. The initial
slope of the uptake curve was used to estimate the rate of tracer
albumin uptake, which was 6 fmol · min1 · 106
cells
1; this value was within the same range as
125I-albumin transendothelial transport of 7.2 fmol · min
1 · 106
cells
1 (see above). Endothelial 125I-albumin
uptake was markedly inhibited at each time point by excess (1.5 mM)
unlabeled albumin (Fig. 4).
|
Concentration dependence of albumin uptake.
Submaximal concentrations of unlabeled albumin produced biphasic
inhibition of tracer albumin uptake (Fig. 5A;
IC50 = 1.15 µM).
Scatchard analysis (Fig. 5B) used to parse the sigmoidal function into its two components showed a 0.87 µM high-affinity component, with maximal binding capacity (Bmax) = 0.47 pmol/106 cells, and a 93.3 µM low-affinity component,
with Bmax = 20.2 pmol/106 cells. From
these data, we determined the total albumin uptake (labeled + unlabeled forms) as a function of albumin concentration (Fig.
5C). The cellular uptake of albumin was dependent on albumin concentration; the steepest region of concentration dependency was
between 105 and 10
3 M albumin. The smooth
curve in Fig. 5C predicts an EC50 of ~100 µM and saturation of transport at ~3 mM albumin.
|
Confocal fluorescence imaging of albumin uptake.
We visualized the uptake of albumin in caveolae by colocalization of
fluorescent forms of albumin, cholera toxin subunit B, and anti-gp60
antibody. Cholera toxin subunit B was used as a specific marker for
caveolae, because it labels the caveolae-specific ganglioside GM1
(14); gp60 was previously shown to be associated with
endothelial caveolae (13). After 30 min of incubation with these fluorescent probes at 37°C, cells were acid washed to remove residual cell surface probe, fixed, and stained with the nuclear marker
DAPI (1 µg/ml) or anti-caveolin-1 antibody plus Alexa 350-labeled secondary antibody. High-resolution confocal images (<1.0 µm optical thickness) in Fig. 6A show
internalized Alexa 488-albumin and Cy3-gp60 antibody, together with
caveolin-1 immunostaining near the apical cell surface. Coincident
staining of gp60 and albumin and colocalization of all three probes
were apparent in the overlay. In other experiments, fluorescent albumin
was coincubated with fluorescent cholera toxin subunit B. Figure
6B shows the confocal images of internalized Alexa
594-cholera toxin subunit B and Alexa 488-albumin, together with DAPI.
The fluorescence of albumin and cholera toxin was coincident in the
merged image, indicating albumin's association with caveolae.
|
|
Albumin Binding to Endothelial Cell Surface
Competition between endothelial cell surface labeled and unlabeled
albumin.
Agonist competition binding studies were made using RLMVEC in cold
conditions (4°C) to abolish tracer endocytosis and internalization. Cells were incubated with 125I-albumin in the presence or
absence of unlabeled albumin (1012-10
3
M) for 30 min. Unlabeled albumin reduced the specific binding of
125I-albumin from 17.5 to 2.7 ± 0.4 fmol/106 cells. The IC50 and Hill coefficient
fitted to the data were 4.5 nM and 0.28, respectively, suggesting the
existence of more than one albumin binding site on the RLMVEC surface
(Fig. 8A). Scatchard analysis
of the binding data (Fig. 8B) demonstrated two albumin
binding sites, with affinity (KD) values of 13.5 nM and 1.6 µM, respectively, and corresponding Bmax
values of 24.2 fmol/106 cells and 2.4 pmol/106
cells. The lower-affinity site accounted for >98% of the binding.
|
Displacement of albumin from cell surface binding sites by anti-gp60 antibody. Pretreatment of RLMVEC monolayers for 1 h at 4°C with a 1:200 dilution of anti-gp60 antibody decreased 125I-albumin binding by 47.8 ± 5.1% (n = 3) relative to control antibody. The tracer albumin and the specific anti-gp60 antibody competed for the same membrane binding sites. Thus high- and low-affinity binding sites detected on RLMVEC may represent different states of gp60.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
RLMVEC monolayers exhibited a high degree of specific 125I-albumin binding, because >80% of total binding was inhibited by excess unlabeled albumin. Although a saturable low-affinity binding site for albumin has been described in bovine pulmonary artery endothelial cells (23) and rat fat tissue microvessel endothelial cells (20), the finding of a second site of much higher affinity is a novel observation. Competition studies of 125I-albumin binding under cold conditions (4°C) to prevent tracer internalization showed that albumin bound to the endothelial cell surface with affinity constants of 13.5 nM (KD1) and 1.6 µM (KD2). On the basis of the corresponding Bmax values, the high-affinity site represented ~1% of the specific albumin binding and averaged 5 × 105 sites/cell. Schnitzer and Oh (21) and Tiruppathi et al. (25) demonstrated that an anti-gp60 antibody displaced the specific binding of 125I-albumin from rat and bovine pulmonary microvascular endothelial cells, consistent with our observations. Thus the specific binding sites for albumin may include gp60.
Because the measured albumin uptake only represents that albumin tracer
internalized by the cells (which thus was present in the lysate from
acid-washed cells), it is likely that uptake data report the
endocytosis of the tracer. At 108-10
3
M unlabeled albumin, we observed progressive inhibition of tracer albumin uptake (Fig. 5A). From Scatchard analysis (Fig.
5B), we determined the apparent albumin binding constants of
the transporter to be 0.87 µM (low affinity) and 93 µM (ultra-low
affinity). The low-affinity uptake value is similar to other reported
low-affinity binding values (20, 23). The low-affinity
albumin binding may represent the tracer albumin, which was initially
bound to a saturable site at the cell surface such as gp60 and was
subsequently internalized by endocytosis. By contrast, the
ultra-low-affinity component may represent tracer albumin sequestered
within a restricted membrane compartment (with limited access to the
extracellular fluid). Endothelial caveolae, which communicate with the
extracellular fluid via narrow (20- to 30-nm) necks (17),
could qualify as such a compartment. Our evidence for this is as
follows: 1) at 4°C when internalization by endocytosis is
completely inhibited, the ultra-low-affinity binding component was not
detected (Fig. 8); 2) at 37°C, methyl-
-cyclodextrin,
which was shown to eliminate caveolae (Fig. 7), markedly inhibited all
components of 125I-albumin uptake (Fig. 2); and
3) Alexa 488-albumin entered the caveolar compartment,
because the fluorophore was shown to colocalize in endocytic vesicles
with Cy3-labeled anti-gp60 antibody (Fig. 6A) and Alexa
594-cholera toxin subunit B (Fig. 6B), the specific caveolae
marker (15).
We used methyl--cyclodextrin as a reagent to address the
relationship between albumin uptake and transport.
Methyl-
-cyclodextrin abolished albumin uptake and transport (Figs. 2
and 7). The albumin transport protocol monitored the transfer of
albumin tracer through the cell monolayer and into the abluminal
chamber. In this assay, the backflux of tracer albumin from the
abluminal compartment was minimal because of dilution of the volume in
the abluminal well, thus allowing a measure of unidirectional albumin
flux. Moreover, we imposed no transendothelial hydrostatic or oncotic pressure gradient, thus rendering negligible the convective movement of
tracer. We infer from the methyl-
-cyclodextrin sensitivity of
transendothelial albumin transport that the diffusional paracellular flux of tracer albumin in RLMVEC was minimal (Fig. 2).
The earliest step in the uptake and transport of albumin through
endothelial cells is the "docking" of albumin on the
caveolae-associated ABPs (2, 6, 7, 13, 19-21, 25, 28,
29). Inasmuch as the transendothelial flux of tracer albumin was
abolished by excess unlabeled albumin (1.5 mM), the albumin
internalized by endothelial cells and transported through the monolayer
is displaceable (Fig. 1). In the presence of a much lower concentration
of unlabeled albumin (1.5 µM), there is a linear relationship between
albumin transport and time (Fig. 1). From the slope of this
relationship, we calculated the rate of tracer albumin transport to be
7.2 fmol albumin · min1 · 106
endothelial cells
1. Importantly, we observed that the
tracer albumin uptake rate of 6 fmol · min
1 · 106
cells
1 (calculated from the initial slope of the uptake
curve in Fig. 4) was comparable to the transport rate.
Analysis of the time course of tracer albumin uptake showed peaks at 15 and 75 min (Fig. 4). A possible interpretation of this complex uptake process is that this represents the reuptake of albumin tracer that has been exocytosed. Recycling of the tracer involving uptake, extrusion, and reuptake could account for the dual uptake peaks.
Anti-gp60 antibody exposure of cells used to deplete the cell surface gp60 (27) reduced albumin uptake and transport in the endothelial barrier at 37°C by ~85% (Fig. 3). This finding is consistent with a role of cell surface gp60 in mediating albumin transport via transcytosis. By contrast, gp60 activation induced by a much briefer exposure to the anti-gp60 antibody plus a secondary antibody [to cross-link gp60 (27)] markedly increased the transport of 125I-albumin. This method of cross-linking is analogous to that induced in activating growth factor receptors, which dimerize, or glycosylphosphatidylinositol-anchored proteins, which cluster in rafts or caveolae, on exposure to specific antibodies (1). Because cross-linking by the anti-gp60 antibody increased albumin uptake and transport at 37°C but blocked albumin binding at 4°C, it is an activating and a blocking antibody, depending on the temperature. The data show that the antibody can compete with albumin for binding to gp60 at 37°C as well as 4°C. However, at 37°C, ~98% of the internalized albumin is in the fluid phase compartment of plasmalemma vesicles, rather than "receptor bound," because it required significantly more unlabeled albumin to antagonize competitively 125I-albumin uptake (Fig. 5A) than 125I-albumin binding (Fig. 8A). The data in Fig. 5B show that the ultra-low-affinity uptake of albumin has a much greater Bmax (20.2 pmol/million cells) than the low-affinity component (0.47 pmol/106 cells), suggesting that fluid-phase endocytosis represents ~98% of the overall uptake of albumin in RLMVEC. Therefore, increased albumin transport induced by gp60 cross-linking appears to be primarily the result of increased fluid-phase albumin transport subsequent to activation of endocytosis.
The model (Fig. 9) predicts that albumin
transport can increase on the basis of activation of gp60 and the
internalization of caveolae carrying albumin in the fluid phase. As
shown in the model, albumin binding to the high-affinity cell surface
gp60 induces clustering of this "receptor" and its association with caveolin-1. Clustered gp60 has a reduced affinity for albumin (in the 1 µM range) that may represent the physiological state of gp60, because
it is constantly exposed to saturating concentrations of albumin.
Clustering of gp60 may, through activation of specific signaling
pathways dependent on Gi and Src (12, 13, 27), induce the release of caveolae from the luminal plasma membrane. Inasmuch as caveolae bud from the membrane in this model, fluid-phase albumin is trapped within these released vesicles. According to our
measurements, albumin uptake by this ultra-low-affinity (in the range
100 µM), high-capacity system represents 98% of total internalized
albumin.
|
What is the previous evidence in favor of transcytosis of albumin in the endothelial cell monolayer? In a series of studies, gp60 activation was shown to stimulate apical-to-basolateral migration of vesicles as monitored using interfacial fluorescent probes RH414 and FM1-43 (12, 13). Activation of gp60 also increased the transport of albumin and horseradish peroxidase without altering the hydraulic conductivity or decreasing transendothelial electrical resistance in bovine endothelial cells (13, 27). These findings suggest transport of albumin via nonhydraulic or transcellular pathways utilizing vesicle carriers. Studies also showed (28), using distinct interfacial and paracellular probes, that gp60 activation selectively increased the flux of the interfacial probes, suggesting activation of plasmalemmal vesicle trafficking.
In summary, our data support the hypothesis that 1) transendothelial albumin transport in the RLMVEC used in the present study is dominated by the transcytosis pathway, 2) this mode of transport is saturable, 3) binding of albumin to a limited number of high-affinity sites on the endothelial cell may activate albumin transport by the release of caveolae from the membrane, and 4) the bulk of the albumin within the transport vesicles is in the fluid phase. Inasmuch as the specific binding sites for albumin on the endothelial cell surface are high affinity relative to the physiological concentrations of serum and interstitial albumin, this implies that albumin transcytosis should be continuously active. This is evident for the numerous vesicles seen in resting endothelial cells in situ that comprise ~20% of the cell volume (17). However, as our data demonstrate, albumin uptake is not saturated at physiological concentrations of albumin. Rather, the uptake is maximal in the presence of ~3 mM albumin, which is five times greater than plasma albumin concentration, suggesting the potential for increased albumin transport via transcytosis in response to activation of specific signaling pathways.
![]() |
ACKNOWLEDGEMENTS |
---|
This research was supported in part by National Heart, Lung, and Blood Institute Grants T32 HL-07239 and HL-60678. R. D. Minshall is a Parker B. Francis Fellow in Pulmonary Research.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: R. D. Minshall, University of Illinois at Chicago, Dept. of Pharmacology (m/c 868), 835 S. Wolcott Ave., Chicago, IL 60612 (E-mail: rminsh{at}uic.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajplung.00152.2002
Received 15 May 2002; accepted in final form 14 August 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Anderson, RGW
The caveolae membrane system.
Annu Rev Biochem
67:
199-225,
1998[ISI][Medline].
2.
Antohe, F,
Dobrila L,
Heltianu C,
Siminionescu N,
and
Simionescu M.
Albumin-binding proteins function in the receptor-mediated binding and transcytosis of albumin across cultured endothelial cells.
Eur J Cell Biol
60:
268-275,
1993[ISI][Medline].
3.
Bocci, V.
Efficient labeling of serum proteins with 131I using chloramine-T.
Int J Appl Radiat Isot
15:
449-456,
1964[ISI].
4.
Del Vecchio, PJ,
Siflinger-Birnboim A,
Belloni PN,
Holleran LA,
Lum H,
and
Malik AB.
Culture and characterization of pulmonary microvascular endothelial cells.
In Vitro Cell Dev Biol
28A:
711-715,
1992.
5.
Del Vecchio, PJ,
Siflinger-Birnboim A,
Shepard JM,
Bizios R,
Cooper JA,
and
Malik AB.
Endothelial monolayer permeability to macromolecules.
Federation Proc
46:
2511-2515,
1987[ISI][Medline].
6.
Ghinea, N,
Eskenasy M,
Simionescu M,
and
Simionescu N.
Endothelial albumin binding proteins are membrane-associated components exposed on the cell surface.
J Biol Chem
264:
4755-4758,
1989
7.
Ghinea, N,
Fixmanm A,
Alexandru D,
Popov D,
Hasu M,
Ghitescu L,
Eskenasy M,
Simionescu M,
and
Simionescu N.
Identification of albumin binding proteins in capillary endothelial cells.
J Cell Biol
107:
231-239,
1988[Abstract].
8.
Ghitescu, L,
Fixman A,
Simionescu M,
and
Simionescu N.
Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis.
J Cell Biol
102:
1304-1311,
1986[Abstract].
9.
John, TA,
Vogel SM,
Minshall RD,
Ridge K,
Tiruppathi C,
and
Malik AB.
Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung.
J Physiol
533:
547-559,
2001
10.
Keller, P,
and
Simons K.
Cholesterol is required for surface transport of influenza virus hemagglutinin.
J Cell Biol
140:
1357-1367,
1998
11.
Milici, AJ,
Watrous NE,
Stukenbrok H,
and
Palade GE.
Transcytosis of albumin in capillary endothelium.
J Cell Biol
105:
2603-2612,
1987[Abstract].
12.
Minshall, RD,
Tiruppathi C,
Vogel SM,
and
Malik AB.
Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function.
Histochem Cell Biol
117:
105-112,
2002[ISI][Medline].
13.
Minshall, RD,
Tiruppathi C,
Vogel SM,
Niles WD,
Gilchrist A,
Hamm HE,
and
Malik AB.
Endothelial cell-surface gp60 activates vesicle formation and trafficking via Gi-coupled Src kinase signaling pathway.
J Cell Biol
150:
1059-1069,
2000.
14.
Niles, WD,
and
Malik AB.
Endocytosis and exocytosis events regulate vesicle traffic in endothelial cells.
J Membr Biol
167:
85-101,
1999[ISI][Medline].
15.
Parton, RG.
Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae.
J Histochem Cytochem
42:
155-166,
1994
16.
Predescu, D,
Horvat R,
Predescu S,
and
Palade GE.
Transcytosis in the continuous endothelium of the myocardial microvasculature is inhibited by N-ethylmaleimide.
Proc Natl Acad Sci USA
91:
3014-3018,
1994[Abstract].
17.
Predescu, D,
and
Palade GE.
Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium.
Am J Physiol Heart Circ Physiol
265:
H725-H733,
1993
18.
Predescu, D,
Simionescu M,
Simionescu N,
and
Palade GE.
Binding and transcytosis of glycoalbumin by microvascular endothelium for the murine myocardium: evidence that glycoalbumin behaves as a bifunctional ligand.
J Cell Biol
107:
1729-1738,
1988[Abstract].
19.
Schnitzer, JE.
Gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis.
Am J Physiol Heart Circ Physiol
262:
H246-H254,
1992
20.
Schnitzer, JE,
Carley WW,
and
Palade GE.
Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein.
Proc Natl Acad Sci USA
85:
6773-6777,
1988[Abstract].
21.
Schnitzer, JE,
and
Oh P.
Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins.
J Biol Chem
269:
6072-6082,
1994
22.
Siflinger-Birnboim, A,
Cooper JA,
del Vecchio PJ,
Lum H,
and
Malik A.
Selectivity of the endothelial monolayer: effects of increased permeability.
Microvasc Res
36:
216-227,
1988[ISI][Medline].
23.
Siflinger-Birnboim, A,
Schnitzer J,
Lum H,
Blumenstock FA,
Shen CP,
del Vecchio PJ,
and
Malik AB.
Lectin binding to gp60 decreases specific albumin binding and transport in pulmonary artery endothelial monolayers.
J Cell Physiol
149:
575-584,
1991[ISI][Medline].
24.
Simionescu, N.
Transcytosis and traffic of membranes in the endothelial cell.
In: International Cell Biology, edited by Schweiger HG.. Berlin: Springer-Verlag, 1981, p. 657-672.
25.
Tiruppathi, C,
Finnegan A,
and
Malik AB.
Isolation and characterization of a cell surface albumin binding protein from vascular endothelial cells.
Proc Natl Acad Sci USA
93:
250-254,
1996
26.
Tiruppathi, C,
Lum H,
Andersen TT,
Fenton JW, II,
and
Malik AB.
Thrombin receptor 14-amino acid peptide binds to endothelial cells and stimulates calcium transients.
Am J Physiol Lung Cell Mol Physiol
263:
L595-L601,
1992
27.
Tiruppathi, C,
Song W,
Bergenfeldt M,
Sass P,
and
Malik AB.
Gp60 activation mediates albumin transcytosis in endothelial cells by a tyrosine kinase-dependent pathway.
J Biol Chem
272:
25968-25975,
1997
28.
Vogel, SM,
Easington CR,
Minshall RD,
Niles WD,
Tiruppathi C,
Hollenberg SM,
Parrillo JE,
and
Malik AB.
Evidence of transcellular permeability pathway in microvessels.
Microvasc Res
61:
87-101,
2001[ISI][Medline].
29.
Vogel, SM,
Minshall RD,
Pilipovic M,
Tiruppathi C,
and
Malik AB.
Activation of 60 kDa albumin-binding protein (gp60) stimulates albumin transcytosis in the intact pulmonary microvessel.
Am J Physiol Lung Cell Mol Physiol
281:
L1512-L1522,
2001